Credo Technology Group (NASDAQ:CRDO) reported quarterly earnings of $0.03 per share which met the analyst consensus estimate. The company reported quarterly sales of $46.50 million which beat the analyst consensus estimate of $45.70 million by 1.75 percent.
Amarin Announces Vascepa Approved To Reduce Cardiovascular Risk In Kingdom Of Saudi Arabia
-- VASCEPA® Approved in KSA To Reduce the Risk of Cardiovascular (CV) Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT--
